Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 67, Issue 4, Pages 775-781Publisher
SPRINGER
DOI: 10.1007/s00280-010-1375-0
Keywords
Bladder cancer; Orthotopic animal model; PVP-hypericin; HAL
Categories
Funding
- Fonds voor Wetenschappelijk Onderzoek-Vlaanderen (F.W.O-Vlaanderen)
- K.U.Leuven (onderzoekstoelage)
- Sanochemia Pharmazeutika AG (Austria)
Ask authors/readers for more resources
In this preclinical study, we examined the biodistribution of hypericin formulated as its water-soluble PVP-hypericin complex in the different layers (urothelium, submucosa, muscle) of a normal rat bladder and a rat bladder bearing a malignant urothelium composed of syngeneic AY-27 tumor cells. The results were compared with the biodistribution of hexaminolevulinate (HAL)-induced protoporphyrin IX (PpIX). Freshly prepared PVP-hypericin and HAL solutions were instilled in both normal as well as tumor-bearing rat bladders. Following instillation, bladders were removed and snap frozen in liquid nitrogen. Fluorescence of PVP-hypericin or PpIX-induced HAL was measured in the bladder layers and quantified using image analysis software. The results of these experiments show that PVP-hypericin (30 mu M) accumulated about 3.5-fold more in malignant urothelial tissue when compared to normal urothelium, whereas PpIX accumulated to the same extent in malignant and normal urothelium, both after intrabladder instillation of 8 or 16 mM HAL. Besides, PVP-hypericin and PpIX accumulated selectively in the urothelium with a tumor-to-muscle ratio of 30.6 for PVP-hypericin and 3.7-8.3 for 16 and 8 mM HAL, respectively. This study shows that PVP-hypericin appears to have great potential as a photodynamic agent against non-muscle-invasive bladder cancers after intravesical administration, with a limited risk of affecting the deeper layers of the bladder.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available